Considerations and practical implications of performing a phenotypic CRISPR/Cas survival screen

被引:4
|
作者
Ashoti, Ator [1 ]
Limone, Francesco [2 ,3 ]
van Kranenburg, Melissa [1 ]
Alemany, Anna [1 ,6 ]
Baak, Mirna [1 ]
Vivie, Judith [1 ,4 ]
Piccioni, Frederica [5 ]
Dijkers, Pascale F. [1 ,6 ]
Creyghton, Menno [1 ,7 ]
Eggan, Kevin [2 ,3 ]
Geijsen, Niels [1 ]
机构
[1] Hubrecht Inst, Dev Biol & Stem Cell Res, Utrecht, Netherlands
[2] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA
[3] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA
[4] Single Cell Discoveries, Utrecht, Netherlands
[5] Broad Inst, Cambridge, MA USA
[6] Leiden Univ, Dept Anat & Embryol, Med Ctr, Leiden, Netherlands
[7] Erasmus MC, Dept Dev Embryol, Rotterdam, Netherlands
来源
PLOS ONE | 2022年 / 17卷 / 02期
关键词
VIRUS ENTRY REQUIRES; DUX4; EXPRESSION; RESTRICTION ENZYMES; CANDIDATE GENE; DNA-CLEAVAGE; CELL; MODEL; SEQUENCE; RECEPTOR; LINE;
D O I
10.1371/journal.pone.0263262
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Genome-wide screens that have viability as a readout have been instrumental to identify essential genes. The development of gene knockout screens with the use of CRISPR-Cas has provided a more sensitive method to identify these genes. Here, we performed an exhaustive genome-wide CRISPR/Cas9 phenotypic rescue screen to identify modulators of cytotoxicity induced by the pioneer transcription factor, DUX4. Misexpression of DUX4 due to a failure in epigenetic repressive mechanisms underlies facioscapulohumeral muscular dystrophy (FHSD), a complex muscle disorder that thus far remains untreatable. As the name implies, FSHD generally starts in the muscles of the face and shoulder girdle. Our CRISPR/Cas9 screen revealed no key effectors other than DUX4 itself that could modulate DUX4 cytotoxicity, suggesting that treatment efforts in FSHD should be directed towards direct modulation of DUX4 itself. Our screen did however reveal some rare and unexpected genomic events, that had an important impact on the interpretation of our data. Our findings may provide important considerations for planning future CRISPR/Cas9 phenotypic survival screens.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Key elements for designing and performing a CRISPR/Cas9-based genetic screen
    Shang, Wanjing
    Wang, Fei
    Fan, Gaofeng
    Wang, Haopeng
    JOURNAL OF GENETICS AND GENOMICS, 2017, 44 (09) : 439 - 449
  • [2] Key elements for designing and performing a CRISPR/Cas9-based genetic screen
    Wanjing Shang
    Fei Wang
    Gaofeng Fan
    Haopeng Wang
    JournalofGeneticsandGenomics, 2017, 44 (09) : 439 - 449
  • [3] CRISPR/Cas-Mediated Base Editing: Technical Considerations and Practical Applications
    Molla, Kutubuddin A.
    Yang, Yinong
    TRENDS IN BIOTECHNOLOGY, 2019, 37 (10) : 1121 - 1142
  • [4] A comprehensive phenotypic CRISPR-Cas9 screen of the ubiquitin pathway uncovers roles of ubiquitin ligases in mitosis
    Hundley, Frances V.
    Delgado, Nerea Sanvisens
    Marin, Harold C.
    Carr, Kaili L.
    Tian, Ruilin
    Toczyski, David P.
    MOLECULAR CELL, 2021, 81 (06) : 1319 - 1336.e9
  • [5] CRISPR-Cas9 screen identifies oxidative phosphorylation as essential for cancer cell survival at low extracellular pH
    Michl, Johanna
    Wang, Yunyi
    Monterisi, Stefania
    Blaszczak, Wiktoria
    Beveridge, Ryan
    Bridges, Esther M.
    Koth, Jana
    Bodmer, Walter F.
    Swietach, Pawel
    CELL REPORTS, 2022, 38 (10):
  • [6] CRISPR/Cas9 screen of B cell differentiation pathways
    Mulpur, Roy Neal
    Patterson, Dillon
    Scharer, Christopher D.
    Boss, Jeremy M.
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [7] Multiplex CRISPR/Cas screen in regenerating haploid limbs of chimeric Axolotls
    Sanor, Lucas D.
    Flowers, Grant Parker
    Crews, Craig M.
    ELIFE, 2020, 9
  • [8] Technical considerations for the use of CRISPR/Cas9 in hematology research
    Gundry, Michael C.
    Dever, Daniel P.
    Yudovich, David
    Bauer, Daniel E.
    Haas, Simon
    Wilkinson, Adam C.
    Singbrant, Sofie
    EXPERIMENTAL HEMATOLOGY, 2017, 54 : 4 - 11
  • [9] CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers
    Kostyushev, Dmitry
    Kostyusheva, Anastasiya
    Ponomareva, Natalia
    Brezgin, Sergey
    Chulanov, Vladimir
    NUCLEIC ACID THERAPEUTICS, 2022, 32 (01) : 14 - 28
  • [10] A CRISPR/Cas9 Library Screen in Patients' Leukemia Cells In Vivo
    Bahrami, Ehsan
    Becker, Martin
    Wirth, Anna-Katharina
    Schmid, Jan Phillip
    Herold, Tobias
    Oellinger, Rupert
    Rad, Roland
    Jeremias, Irmela
    BLOOD, 2019, 134